PT1490405E - Anticorpos humanos anti-ligando de hfas antagonistas e fragmentos dos mesmos - Google Patents
Anticorpos humanos anti-ligando de hfas antagonistas e fragmentos dos mesmos Download PDFInfo
- Publication number
- PT1490405E PT1490405E PT03716239T PT03716239T PT1490405E PT 1490405 E PT1490405 E PT 1490405E PT 03716239 T PT03716239 T PT 03716239T PT 03716239 T PT03716239 T PT 03716239T PT 1490405 E PT1490405 E PT 1490405E
- Authority
- PT
- Portugal
- Prior art keywords
- seq
- antibody
- hfasl
- antigen
- amino acid
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2875—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF/TNF superfamily, e.g. CD70, CD95L, CD153, CD154
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Virology (AREA)
- Immunology (AREA)
- Molecular Biology (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Diabetes (AREA)
- Pulmonology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Genetics & Genomics (AREA)
- Rheumatology (AREA)
- Neurology (AREA)
- Biophysics (AREA)
- Urology & Nephrology (AREA)
- Biochemistry (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Vascular Medicine (AREA)
- Neurosurgery (AREA)
- Biotechnology (AREA)
- Emergency Medicine (AREA)
- Endocrinology (AREA)
- Hematology (AREA)
- Obesity (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US36705402P | 2002-03-21 | 2002-03-21 | |
| US40976802P | 2002-09-10 | 2002-09-10 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PT1490405E true PT1490405E (pt) | 2007-11-07 |
Family
ID=28457146
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PT03716239T PT1490405E (pt) | 2002-03-21 | 2003-03-12 | Anticorpos humanos anti-ligando de hfas antagonistas e fragmentos dos mesmos |
Country Status (15)
| Country | Link |
|---|---|
| US (1) | US7262277B2 (enExample) |
| EP (1) | EP1490405B1 (enExample) |
| JP (1) | JP2005520523A (enExample) |
| CN (1) | CN1283662C (enExample) |
| AT (1) | ATE370970T1 (enExample) |
| AU (1) | AU2003219954B2 (enExample) |
| BR (1) | BR0308401A (enExample) |
| CA (1) | CA2478386A1 (enExample) |
| DE (1) | DE60315815T2 (enExample) |
| DK (1) | DK1490405T3 (enExample) |
| ES (1) | ES2291626T3 (enExample) |
| IL (1) | IL164011A0 (enExample) |
| MX (1) | MXPA04009148A (enExample) |
| PT (1) | PT1490405E (enExample) |
| WO (1) | WO2003079750A2 (enExample) |
Families Citing this family (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AR045563A1 (es) * | 2003-09-10 | 2005-11-02 | Warner Lambert Co | Anticuerpos dirigidos a m-csf |
| BRPI0416262B1 (pt) * | 2003-11-05 | 2022-04-12 | Roche Glycart Ag | Anticorpo anti-cd20 humano tipo ii humanizado, seu método de produção, seus usos, bem como polinucleotídeo isolado, vetor de expressão e composição farmacêutica |
| JP4588763B2 (ja) | 2004-02-06 | 2010-12-01 | ユニバーシティー オブ マサチューセッツ | クロストリジウム・ディフィシル（Ｃｌｏｓｔｒｉｄｉｕｍｄｉｆｆｉｃｉｌｅ）毒素に対する抗体およびその使用 |
| KR101460932B1 (ko) * | 2005-08-26 | 2014-11-12 | 로슈 글리카트 아게 | 변형된 세포 신호 활성을 가진 개질된 항원 결합 분자 |
| MX2010006450A (es) * | 2007-12-12 | 2010-12-15 | Pincell Srl | Remedios para penfigo que contienen anticuerpos antiligando de fas. |
| WO2010006772A2 (en) * | 2008-07-14 | 2010-01-21 | Deutsches Krebsforschungszentrum Stiftung des öffentlichen Rechts | Use of cd95 inhibitors for the treatment of inflammatory disorders |
| PT2376536E (pt) * | 2008-12-12 | 2015-05-11 | Pincell Srl | Remédios para pênfigo contendo anticorpos anti-ligando de faz |
| CN102337298B (zh) * | 2011-08-19 | 2013-11-06 | 黄开红 | 一种输送siRNA的免疫纳米载体及其制备方法和应用 |
| JP2016508606A (ja) * | 2013-02-01 | 2016-03-22 | アンスティチュ ナショナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシュ メディカル | トリプルネガティブ乳ガンにおける転移を予測及び予防するための方法 |
| EP2992330B1 (en) * | 2013-04-29 | 2018-04-18 | Apogenix AG | Method of diagnosing cancer |
| EP3137909B1 (en) * | 2014-04-29 | 2018-06-06 | Apogenix AG | Diagnostic anti-cd95l antibody |
| US20220289827A1 (en) * | 2021-03-11 | 2022-09-15 | Washington University | Neutralizing antibodies to sars-cov-2 and its variants |
| WO2023138521A1 (zh) * | 2022-01-21 | 2023-07-27 | 北京三诺佳邑生物技术有限责任公司 | 特异性识别FasL的抗体及其应用 |
| CN116829594A (zh) * | 2022-01-21 | 2023-09-29 | 北京三诺佳邑生物技术有限责任公司 | 特异性识别FasL的抗体及其应用 |
| WO2023208990A1 (en) | 2022-04-26 | 2023-11-02 | F. Hoffmann-La Roche Ag | Combination therapy for the treatment of cancer comprising a fas axis antagonist and a t-reg cell depleting agent antagonist, |
| WO2024193714A1 (zh) * | 2023-03-23 | 2024-09-26 | 科济生物医药（上海）有限公司 | 细胞免疫疗法的组合物和方法 |
| EP4474395A1 (en) * | 2023-06-06 | 2024-12-11 | PinCell S.r.l. | Anti-fas ligand (fasl) antibodies in the treatment of sjs/ten diseases |
| CN120981482A (zh) * | 2023-03-24 | 2025-11-18 | 平切尔有限责任公司 | 抗FAS配体（FasL）抗体治疗SJS/TEN疾病 |
| WO2025196289A1 (en) | 2024-03-22 | 2025-09-25 | Pincell S.R.L. | New target affinity and specificity of anti sfas-l antibody, pc111 |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH08127594A (ja) | 1993-11-10 | 1996-05-21 | Mochida Pharmaceut Co Ltd | Ｆａｓ抗原に結合する新規蛋白質およびそれをコードするＤＮＡ |
| EP0739350B1 (en) | 1994-01-07 | 2008-02-27 | Mochida Pharmaceutical Co., Ltd. | Ligand that binds fas antigen |
| US6096312A (en) * | 1995-06-30 | 2000-08-01 | Mochida Pharmaceutical Co., Ltd. | Agent for suppressing a reduction of CD4+ lymphocytes |
| CN1196733A (zh) * | 1995-06-30 | 1998-10-21 | 持田制药株式会社 | 抗Fas配体抗体和利用抗Fas配体抗体的测定方法 |
| US6114507A (en) * | 1995-06-30 | 2000-09-05 | Mochida Pharmaceutical Co., Ltd. | Anti-Fas ligand antibody and assay method using the anti-Fas ligand antibody |
-
2003
- 2003-03-12 EP EP03716239A patent/EP1490405B1/en not_active Expired - Lifetime
- 2003-03-12 AT AT03716239T patent/ATE370970T1/de not_active IP Right Cessation
- 2003-03-12 WO PCT/US2003/006155 patent/WO2003079750A2/en not_active Ceased
- 2003-03-12 MX MXPA04009148A patent/MXPA04009148A/es active IP Right Grant
- 2003-03-12 BR BR0308401-9A patent/BR0308401A/pt not_active IP Right Cessation
- 2003-03-12 CA CA002478386A patent/CA2478386A1/en not_active Abandoned
- 2003-03-12 IL IL16401103A patent/IL164011A0/xx unknown
- 2003-03-12 PT PT03716239T patent/PT1490405E/pt unknown
- 2003-03-12 DK DK03716239T patent/DK1490405T3/da active
- 2003-03-12 AU AU2003219954A patent/AU2003219954B2/en not_active Ceased
- 2003-03-12 DE DE60315815T patent/DE60315815T2/de not_active Expired - Lifetime
- 2003-03-12 US US10/506,743 patent/US7262277B2/en not_active Expired - Fee Related
- 2003-03-12 ES ES03716239T patent/ES2291626T3/es not_active Expired - Lifetime
- 2003-03-12 CN CNB038064030A patent/CN1283662C/zh not_active Expired - Fee Related
- 2003-03-12 JP JP2003577595A patent/JP2005520523A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| ATE370970T1 (de) | 2007-09-15 |
| CN1642980A (zh) | 2005-07-20 |
| WO2003079750A3 (en) | 2004-05-13 |
| CA2478386A1 (en) | 2003-10-02 |
| DE60315815D1 (de) | 2007-10-04 |
| IL164011A0 (en) | 2005-12-18 |
| AU2003219954B2 (en) | 2006-11-09 |
| DE60315815T2 (de) | 2008-05-21 |
| EP1490405A2 (en) | 2004-12-29 |
| US7262277B2 (en) | 2007-08-28 |
| MXPA04009148A (es) | 2005-02-28 |
| AU2003219954A1 (en) | 2003-10-08 |
| US20050106140A1 (en) | 2005-05-19 |
| WO2003079750A2 (en) | 2003-10-02 |
| EP1490405B1 (en) | 2007-08-22 |
| DK1490405T3 (da) | 2007-12-27 |
| CN1283662C (zh) | 2006-11-08 |
| BR0308401A (pt) | 2005-03-29 |
| ES2291626T3 (es) | 2008-03-01 |
| EP1490405A4 (en) | 2005-09-14 |
| JP2005520523A (ja) | 2005-07-14 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ES2526990T3 (es) | Anticuerpos humanos anti-hTNFSF13b antagonistas | |
| KR102570405B1 (ko) | Il-7r 알파 서브유닛에 대한 항체 및 이의 용도 | |
| PT1490405E (pt) | Anticorpos humanos anti-ligando de hfas antagonistas e fragmentos dos mesmos | |
| CN100471871C (zh) | 治疗性人抗－il－1r1单克隆抗体 | |
| BR112021008486A2 (pt) | Anticorpo biespecífico e seu uso | |
| US20250353915A1 (en) | Antibodies to galectin-3 and methods of use thereof | |
| JP2022519340A (ja) | ヒトｉｌ４ｒａに対する抗体及びその使用 | |
| NO338054B1 (no) | Humant monoklonalt antistoff mot IL-8, fremgangsmåte for fremstilling av antistoffet, farmasøytisk sammensetning som omfatter antistoffet, og anvendelse derav. | |
| JP2005200421A (ja) | 選択的ｏｐｇｌ経路インヒビターとしてのヒト抗ｏｐｇｌ中和抗体 | |
| RS56368B1 (sr) | Antitela na humani gdf8 | |
| US20240026009A1 (en) | Antibodies to galectin-3 and methods of use thereof | |
| KR102862077B1 (ko) | 인간화 항-n-절단 아밀로이드 베타 단일 클론 항체 | |
| JP7740730B2 (ja) | 抗ｌ１ｃａｍ抗体及びその使用 | |
| BR112019024544A2 (pt) | Proteínas enxertadas com anticorpo-citocina e métodos de uso para distúrbios relacionados à imunidade | |
| JP2022527372A (ja) | 抗インテグリン抗体及びそれらの使用 | |
| JP2023538379A (ja) | 抗ｐａｒ－２抗体及びそれらの使用方法 | |
| WO2023174039A1 (en) | Masp-2-targetting antibodies and uses thereof | |
| WO2024230774A9 (en) | Bdca2-targeting antibodies and uses thereof | |
| WO2024188356A1 (en) | Ilt7-targeting antibodies and uses thereof | |
| AU2024270449A1 (en) | Bdca2-targeting antibodies and uses thereof | |
| CN121194991A (zh) | Bdca2靶向抗体及其用途 |